

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED 億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1061)

ANNOUNCEMENT

UPDATE ON THE COMMERCIALISATION OF THE PRESERVATIVE-FREE SINGLE-DOSE TOBRAMYCIN EYE DROPS IN CHINA

Reference is made to the announcement of Essex Bio-Technology Limited (“Essex”) dated 13 June 2017 (“Announcement”). Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that 珠海億勝生物製藥有限公司 (Zhuhai Essex Bio-Pharmaceutical Co., Ltd*), an indirect wholly-owned subsidiary of Essex, has successfully obtained a 藥品GMP 證書 (Certificate of Good Manufacturing Practices for Pharmaceutical Products*) (“GMP Certificate”) in respect of the preservative-free single-dose Tobramycin Eye Drops (妥布霉素滴眼液) issued by 廣東省食品藥品監督管理局 (Guangdong Provincial Food and Drug Administration), which is valid up to 29 March 2023.

Following the approval, Essex becomes the first company to commercialise the preservative-free single-dose Tobramycin Eye Drops in China. The preservative-free single-dose Tobramycin Eye Drops is an ophthalmic anti-infective product.

With the grant of the GMP Certificate, the Group expects to launch its Tobramycin Eye Drops in the market in the second quarter of 2018, which will boost the Group’s competitive position in the eye care industry.

On behalf of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 11 April 2018

Executive directors of the Company as at the date of this announcement are Mr Ngiam Mia Je Patrick, Mr Fang Haizhou and Mr Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr Fung Chi Ying, Mr Mauffrey Benoit Jean Marie and Ms Yeow Mee Mooi.

* For identification purpose only